瑞博生物:已在欧盟提交RBD3133注射液用于治疗超重及肥胖症的I期临床试验申请

智通财经
Oct 08
【瑞博生物:已在欧盟提交RBD3133注射液用于治疗超重及肥胖症的I期临床试验申请】10月8日早间,瑞博生物在港交所公告,已在欧盟提交公司靶向INHBE的siRNA产品RBD3133注射液以超重及肥胖症为治疗适应症的I期临床试验申请。RBD3133注射液旨在选择性沉默INHBE。人类遗传学研究显示,携带天然INHBE功能丧失变异的个体具有较健康的脂肪分布、改善的代谢特征,以及较低冠心病及2型糖尿病预估风险。该等发现支持INHBE作为治疗肥胖症及相关代谢疾病的极具潜力治疗靶点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10